Sun Pharmaceutical Industries Ltd. has announced entering into a license and supply agreement with Italy’s Cassiopea S.p.A. that will give the Indian company rights to market Winlevi (clascoterone) 1% cream in the US and Canada. The companies expect to make Winlevi available in the US in the fourth quarter of 2021.
Commenting on the partnership, Abhay Gandhi, CEO, North America of Sun Pharma, said the company was “pleased to enter
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?